Withdrawal: Makena

Apr. 2023Pharmacy Updates

On March 7, 2023, Covis Pharma announced that it is withdrawing Makena (hydroxyprogesterone caproate injection; also referred to as 17-OHPC) from the market. This drug is used to reduce the risk of preterm birth in women who are pregnant with one baby and have a history of spontaneous preterm birth. Read more about the Makena withdrawal.

Recent Announcements

Voluntary nationwide recall: Famotidine (Fresenius – November)

Fresenius Kabi USA, LLC is recalling three lots (6133156, 6133194, and 6133388) of Famotidine Injection, USP, 20 mg per 2 mL. Famotidine is used to treat excessive secretion of stomach acid or stomach ulcers.

Nov. 2025Pharmacy Updates

Medicaid provider update: High-cost Medicaid drug billing

Billing requirements for Medicaid-covered drugs

Nov. 2025Important Notices

Training Webinar: Conversio Health COPD Management Program

Please join us for a live training webinar for primary care providers and pulmonologists by UPMC Health Plan that will provide an overview of a comprehensive COPD management program from Conversio Health.

Nov. 2025Education/Webinars